Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …

Children aged 0–2 years (ie, infants) with acute myeloid leukemia (AML) are a peculiar
subgroup of patients in the childhood AML scenario. They present with distinctive biological …

Comprehensive clinical studies of patients with acute megakaryoblastic leukemia (AMKL)
are lacking. We performed an international retrospective study on 490 patients (age≤ 18 …

The presence of chromosomal abnormalities is one of the most important criteria for
leukaemia diagnosis and management. Infant leukaemia is a rare disease that affects …

Highlights•Genetic and epigenetic traits distinguishing pediatric and adult acute myeloid
leukemia (AML) are reviewed.•Insights into stem cell age and pathogenesis of AML are …

Core-binding factor acute myeloid leukemia (CBF-AML)–including AML with t (8; 21) and
AML with inv (16)–accounts for about 15% of adult AML and is associated with a relatively …

Art. 1.1475/ringraziamenti Page 1 Abstract. – OBJECTIVE: Acute myeloid leukemia (AML) is the
second leading leukemia in children. There is growing evidence that microRNAs (miRNAs) are …

Summary The World Health Organization (WHO) classification of myeloid leukaemia was
revised in 2008. It incorporates newly recognized entities and emphasizes the pivotal role of …

Acute leukemia is a worldwide disease with an incidence of approximately 4/100 000 per
year; 70% of the cases are acute myeloid leukemia (AML). The salient pathologic feature of …